Search results for Obiltoxaximab

Obiltoxaximab, Abbexa, abx831343

Obiltoxaximab is a monoclonal antibody biosimilar expressed in CHO cells, targeting Bacillus anthracis Anthrax Protective Antigen, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Obiltoxaximab ELISA Kit, ProteoGenix, KPTX290

Description of Obiltoxaximab ELISA Kit Introduction Obiltoxaximab is a monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) in 2016 for the treatment of inhalational anthrax. It is marketed under the brand name Anthim and is the first and only FDA-approved treatment for this potentially deadly infection. Obiltoxaximab works by targeting and neutralizing the anthrax toxin, which is responsible for the symptoms and progression of the disease. In this article, we will explore the structure, activity, and application of the Obiltoxaximab ELISA Kit, which is used to detect and measure levels of this important therapeutic antibody. Structure of Obiltoxaximab Obiltoxaximab is a monoclonal antibody, meaning it is produced by a single type of immune cell and specifically targets a single antigen. It is a fully human IgG1 antibody, meaning it is composed of four protein chains: two heavy chains and two light chains. The heavy chains are responsible for the binding and neutralization of the anthrax toxin, while the light chains help to stabilize the structure of the antibody. The structure of Obiltoxaximab is similar to that of other human antibodies, making it less likely to cause an immune response in patients. Activity of Obiltoxaximab Obiltoxaximab works by binding to the anthrax toxin, which is composed of three proteins: protective antigen (PA), lethal factor (LF), and edema factor (EF). PA is responsible for binding to receptors on host cells and delivering LF and EF into the cell, where they exert their toxic effects. Obiltoxaximab specifically binds to the PA protein, preventing it from attaching to host cells and delivering the lethal and edema factors. This effectively neutralizes the toxin and prevents it from causing further harm to the body. Application of Obiltoxaximab ELISA Kit The Obiltoxaximab ELISA Kit is a diagnostic tool used to detect and measure levels of Obiltoxaximab in patient samples. ELISA stands for Enzyme-Linked Immunosorbent Assay, and it is a commonly used technique in the field of immunology. The kit contains all the necessary reagents and materials to perform the assay, including a plate coated with the antigen (PA) that Obiltoxaximab binds to, as well as enzymes and substrates that produce a color change when the antibody is present. The Obiltoxaximab ELISA Kit is used in clinical settings to monitor the levels of the antibody in patients receiving treatment for inhalational anthrax. It can also be used in research settings to study the pharmacokinetics (movement and breakdown) of Obiltoxaximab in the body. The results of the ELISA can help healthcare providers determine the effectiveness of the treatment and make any necessary adjustments. Conclusion In summary, Obiltoxaximab is a monoclonal antibody that specifically targets the anthrax toxin and neutralizes its effects. The Obiltoxaximab ELISA Kit is a valuable tool for detecting and measuring levels of this important therapeutic antibody in patient samples. With its unique structure and potent activity, Obiltoxaximab has the potential to save lives and improve outcomes in patients with inhalational anthrax.

Obiltoxaximab ELISA Kit, Abbexa, abx395179

Obiltoxaximab ELISA Kit is a quantitative ELISA kit for detection of Obiltoxaximab.Obiltoxaximab (ETI-204, trade name Anthim) is an affinity-enhanced, chimeric IgG1 kappa monoclonal antibody (mAb) developed by Elusys Therapeutics and the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) for the prevention and treatment of inhalational anthrax due to Bacillus anthracis. Obiltoxaximab binds the protective antigen (PA) component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. Obiltoxaximab has been designed to neutralize the free protective antigen of B. anthracis, thereby inhibiting the lethal effects of anthrax toxins. In March 2016, intravenous obiltoxaximab was approved in the USA for the treatment (in combination with appropriate antibacterial drugs) and prophylaxis of inhalational anthrax.

Obiltoxaximab Biosimilar - Research Grade, ichor.bio, ICH5306

Detects human Anthrax PA

Research Grade Obiltoxaximab (JN898016), abinScience, JN898016